Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
426. |
ECCT/16/05/01 | A5338 A5338 An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) |
Principal Investigator(s) 1. David Schnabel Site(s) in Kenya KISUMU CRS |
View |
427. |
ECCT/20/01/01 | LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH A SEQUENTIAL, MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) FOR NON-SPECIALIST TREATMENT OF COMMON MENTAL DISORDERS IN KENYA: LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH (DAPPER) PROJECT (SMART-DAPPER) |
Principal Investigator(s) 1. Anne Muthoni Mathai 2. Susan Meffert Site(s) in Kenya Kisumu County Hospital |
View |
428. |
ECCT/22/05/01 | VICTORION-2 PREVENT A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease |
Principal Investigator(s) 1. Anthony Gikonyo 2. ELIJAH SAMMY NYAINDA OGOLA Site(s) in Kenya 1. The Karen Hospital (Nairobi City county) 2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county) |
View |
429. |
ECCT/15/11/05 | FALCI Study A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya 1. KEMRI Center for Respiratory Diseases Research (Siaya county) 2. KEMRI Walter Reed Kombewa (Kisumu county) 3. KEMRI Kisumu (Kisumu county) |
View |
430. |
ECCT/20/07/02 | RV 460 HIV Vaccine Trial A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine in Healthy HIV Uninfected Adults in Kenya |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI/US MRDA-A/K, KERICHO |
View |